九强生物9月2日公告，公司胃泌素17测定试剂盒（胶乳免疫比浊法）获得北京市药品监督管理局颁发的 医疗器械注册证。本试剂盒用于体外定量测定人血清中胃泌素17（G-17）的含量。 ...

| | 胃泌素 17 测定试剂 盒（胶乳免疫比浊 | 京 械 注 准 20252400795 | Ⅱ | 自批准之日起有效期 至 2030 年 08 月 31 日 | 本试剂盒用于体外定量 测定人血清中胃泌素 17 | | --- | --- | --- | --- | --- | --- | | 序号 1 | 产品名称 法） | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 （G-17）的含量。 | 上述产品医疗器械注册证的取得，丰富了公司产品类别，有利于增强公 司的核心竞争力，对公司未来发展具有正面影响，但对近期的生产经营和业 绩不会产生重大影响，敬请投资者注意风险。 特此公告。 北京九强生物技术股份有限公司 | 证券代码：300406 | 证券简称：九强生物 公告编号：2025-069 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 北京九强生物技术股份有限公司 关于取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北 ...

Core Viewpoint - The report outlines the management of the convertible bond "Jiukang Convertible Bond" issued by Beijing Jiukang Biotechnology Co., Ltd., detailing its issuance, terms, and adjustments to the conversion price due to dividend distributions and share repurchases [3][4][20]. Group 1: Bond Issuance Details - The total issuance amount of the convertible bond is RMB 1.139 billion, with 11,390,000 bonds issued at a face value of RMB 100 each [4][12]. - The bond has a maturity period of 6 years, from June 30, 2022, to June 29, 2028 [5][9]. - The bond's interest rates are structured to increase over the years, starting from 0.3% in the first year to 3.0% in the sixth year [5][9]. Group 2: Conversion Price Adjustments - The initial conversion price was set at RMB 17.63 per share, which was adjusted to RMB 17.53 following a cash dividend distribution [11][12]. - Subsequent adjustments were made to the conversion price due to further cash dividends, resulting in a new conversion price of RMB 17.35 and then RMB 16.95 [15][19]. - The latest adjustment brought the conversion price down to RMB 16.68, effective from September 5, 2025, due to the latest dividend distribution [20]. Group 3: Credit Rating and Management - The bond has been rated AA- by China Chengxin International Credit Rating Co., Ltd., with a stable outlook [9]. - The management of the bond is overseen by China International Capital Corporation, which is responsible for ensuring the interests of bondholders are protected [20].

股票代码：300406 股票简称：九强生物 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 公开发行可转换公司债券 第三次临时受托管理事务报告 （2025 年度） 债券受托管理人 二〇二五年九月 重要声明 本报告依据《公司债券发行与交易管理办法》《北京九强生物技术股份有限 公司与中国国际金融股份有限公司关于向不特定对象发行可转换公司债券之债 券受托管理协议》（以下简称"《受托管理协议》"）《北京九强生物技术股份 有限公司创业板向不特定对象发行可转换公司债券募集说明书》（以下简称"《募 集说明书》"）等相关规定，由本期债券受托管理人中国国际金融股份有限公司 （以下简称"中金公司"）编制。中金公司对本报告中所包含的从上述文件中引 述内容和信息未进行独立验证，也不就该等引述内容和信息的真实性、准确性和 完整性做出任何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为中金公司所作的承诺 或声明。在任何情况下，投资者依据本报告所进行的任何作为或不作为，中金公 司不承担任何责任。 1 中金公司作为 202 ...

证券日报网讯 9月1日晚间，九强生物发布公告称，公司于近期收到中华人民共和国国家知识产权局颁 发的4项专利证书。 （文章来源：证券日报） ...

Group 1 - Weisheng Information won four projects in August with a total amount of 85.5377 million yuan, accounting for 3.12% of the company's total revenue for 2024 [1] - Longqi Technology's shareholder plans to reduce its stake by up to 4.09%, equating to a maximum of 19.1916 million shares [1] - Guojin Modern's subsidiary received a drug registration certificate for injectable Nicardipine, used for treating unstable angina [3][4] Group 2 - SAIC Motor reported a total vehicle sales of 363,400 units in August, a year-on-year increase of 41.04%, with new energy vehicle sales reaching 129,800 units, up 49.89% [5] - Kuka Home plans to invest 1.124 billion yuan to build a self-owned base in Indonesia, aiming to enhance its international strategy [6] - Samsung Medical's subsidiary signed a contract for an intelligent meter project in Egypt worth 58.8 million USD, approximately 419 million yuan [8] Group 3 - North Vehicle Blue Valley's subsidiary reported a total production of 10,587 units in August, a year-on-year decrease of 15.13%, while sales increased by 3.47% [12] - Xianghe Industrial signed contracts worth 400 million yuan for railway fastener system components [13] - Hengrui Medicine's HRS9531 injection has received acceptance for its marketing authorization application [14] Group 4 - Hualu Hengsheng resumed normal production after completing maintenance on production facilities [16] - Shanghai Pharmaceuticals' hydrochloride verapamil injection passed the consistency evaluation for generic drugs [18] - Shanghai Construction received approval for debt financing tools with a registration period of two years [20] Group 5 - Kangli Elevator terminated the sale of its wholly-owned subsidiary due to the buyer's failure to obtain necessary approvals [21] - Times Wan Heng appointed Li Zhizhong as the new deputy general manager [22] - Hanma Technology reported a total truck sales of 1,051 units in August, a year-on-year increase of 58.05% [24] Group 6 - Wenzhou Hongfeng's subsidiary received a utility model patent certificate for a servo adjustment device [26] - Yibin Technology received a project designation from a domestic new energy vehicle company, with an estimated total sales of 243 million yuan over five years [28] - Star Ring Technology's H-share issuance application was accepted by the China Securities Regulatory Commission [30] Group 7 - Microchip Bio's vice president resigned for personal reasons [31] - Zhongxin Co. announced the resignation of a non-independent director due to personal reasons [32] - Changcheng Military Industry's vice chairman resigned due to retirement [35] Group 8 - Jiukang Bio received four invention patent certificates related to detection reagents [36] - Meino Bio's subsidiary changed its registered address [37] - Kuangda Technology announced a potential change in control due to a share transfer [38] Group 9 - China Rare Earth confirmed no undisclosed significant matters amid stock price fluctuations [72]

证券代码：300406 证券简称：九强生物 公告编号：2025-068 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 北京九强生物技术股份有限公司（以下简称"九强生物"或"公司"）于近 期收到中华人民共和国国家知识产权局颁发的 4 项专利证书，具体情况如下： ZL202310 偶联物的制 偶联物在制 ZL202310 中的用途 偶联物在制 ZL202310 中的用途 一、专利基本情况 序号 专利号 专利名称 专利权人 专利类型 申请日期 授权日期 证书号 氢酶突变体相较于野生型 6- 磷酸葡萄糖脱氢酶包含选自以下的一个突变或其 组合：D306C、D375C、G426C。使用本发明的 6- 磷酸葡萄糖脱氢酶突变体所制 备的检测试剂盒，其特异性强、灵敏度高、操作方便、检测时间短、定量准确， 适合高通量检测。 磷酸葡萄糖脱氢酶突变体相较于野生型 6-磷酸葡萄糖脱氢酶包含选自以下的一 个突变或其组合：D306C、D375C、G426C。使用本发明的 6-磷酸葡萄糖脱氢酶突 变体所制备的检测试剂盒 ...

关于公司获得发明专利证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 北京九强生物技术股份有限公司（以下简称"九强生物"或"公司"）于近 期收到中华人民共和国国家知识产权局颁发的 4 项专利证书，具体情况如下： | 序号 | 专利号 | 专利名称 | 专利权人 | 专利类型 | 申请日期 | 授权日期 | 证书号 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | ZL202310 217235.5 | 偶联物的制 备方法 | 九强生物 | 发明 | 2019.12.26 | 2025.08.26第 | 8198527 | 号 | | 2 | ZL202310 553479.0 | 偶联物在制 备检测试剂 中的用途 | 九强生物 | 发明 | 2020.01.07 | 2025.08.26第 | 8193337 | 号 | | 3 | ZL202310 725902.0 | 偶联物在制 备检测试剂 中的用途 | 九强生物 | 发明 | 2020.01.08 | 2025.0 ...

Core Viewpoint - The company has announced an adjustment to the conversion price of its convertible bonds due to changes in its share capital structure following a cash dividend distribution [1][2][4]. Summary by Sections Conversion Price Adjustment Basis - The adjustment of the conversion price is based on the company's regulations regarding changes in share capital, including stock dividends, capital increases, and cash dividends [1][2]. Reason for Adjustment - The conversion price was adjusted because the company repurchased 3,544,084 shares that did not participate in the cash dividend distribution. The total cash dividend distributed was 174,829,363.20 yuan, calculated based on the number of shares participating in the distribution and the dividend per share of 0.30 yuan [2][3]. Result of Adjustment - The conversion price of the "Jiukang Convertible Bonds" will be adjusted from 16.98 yuan per share to 16.68 yuan per share, effective from September 5, 2025. This adjustment reflects the reduction in the cash dividend per share due to the repurchased shares [4].

Core Points - The company has announced its 2025 semi-annual profit distribution plan, which was approved by the shareholders' meeting and the board of directors [2][3] - The distribution plan involves a cash dividend of RMB 3.00 per 10 shares (including tax), with no capital reserve conversion into additional shares or bonus shares [2][3] - The total cash dividend amount is RMB 174,829,363.20 (including tax) [3] - The record date for the distribution is set for September 4, 2025, and the ex-dividend date is September 5, 2025 [5] - The distribution will not include 3,544,084 shares held in the company's repurchase account [6] - The conversion price for the company's convertible bonds will be adjusted from RMB 16.98 to RMB 16.68 per share effective from September 5, 2025 [6]